Logo
ホームページ
当社のモデルを探求してください。
カート
連絡先
購読する
モデル製品
HUGOシリーズ 🌟
HUGO-GT™(ヒト化ゲノムオルソログ)
HUGO-Ab™(抗体開発)
HUGO-Mab™ – 完全ヒトモノクローナル抗体マウス
MouseAtlas モデルライブラリ
期間限定セール
研究用動物モデル
Creマウス系統
ヒト化ターゲット遺伝子モデル
代謝疾患モデル
眼科疾患モデル
神経疾患モデル
自己免疫疾患モデル
免疫不全マウスモデル
ヒト化免疫系マウスモデル
腫瘍学・免疫腫瘍学モデル
新型コロナウイルス感染症(Covid-19)用マウスモデル
細胞株モデル
ノックアウト細胞株製品カタログ
iPS細胞株製品カタログ
腫瘍細胞株製品カタログ
AAV 标準製品カタログ
サービス
前臨床薬効評価
神経科学
アルツハイマー病前臨床CROサービス
パーキンソン病前臨床CROサービス
ハンチントン病前臨床CROサービス
血液脳関門(BBB)研究ソリューション
眼科分野
緑内障前臨床CROサービス
加齢黄斑変性(AMD)前臨床CROサービス
がん研究
PBMCヒト化マウスモデル
ヒト免疫システム(HIS)マウスモデル
代謝・循環器系疾患
抗肥満薬開発向け前臨床CROサービス
自己免疫・炎症疾患
喘息前臨床CROサービス
遺伝子改変動物
ノックアウトマウス
トランスジェニックマウス
ノックインマウス
ノックアウトラット
ノックインラット
トランスジェニックラット
遺伝子改変モデルの作製技術
TurboknockoutTMゲノム標的化技術
ターゲティング遺伝子編集
通常型トランスジェニック
PiggyBacトランスジェネシス
BACトランスジェニック
ES細胞ターゲティング
繁殖・サポートサービス
繫殖サービス
凍結保存および回復
表型解析サービス
BAC改変
ウイルスパッケージング
アデノ関連ウイルス(AAV)パッケージング
レントウイルスパッケージング
アデノウイルスパッケージング
カスタム細胞株作製サービス
誘導多能性幹細胞(iPS細胞)
ノックアウト細胞株
ノックイン細胞株
点変異細胞株
過剰発現細胞株
モダリティ
遺伝子治療
AI駆動型AAV開発
核酸医薬
細胞免疫療法
コミュ二ティー
キャンペーン
イベント・ウェビナー
ニュース
研究情報
資料室
データベース
査読済み文献(引用)
希少疾患データセンター
AbSeek
Cell iGeneEditor™ システム
OriCell 細胞培養関連
会社案内
企業概要
施設概要
動物の健康・福祉
健康報告書
協力企業・代理店
採用情報
お問い合わせ
Login
HomeMouseAtlas
NKG Mouse
製品のお見積りを依頼する
当社のカタログから製品を選択してご注文ください。当社チームが詳細な情報をご連絡いたします。
お名前
メール
電話番号
ご所属機関
職務
カタログの種類
製品名
主な研究分野
当社を知りなったきっかけ?
その他のコメント
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。

NKG Mouse

製品名
NKG Mouse
製品ID
C001316
系統名
NOD.Cg-PrkdcscidIl2rgem1cya/Cya
背景情報
NOD.Cg
Coat Color
White
Breeding Strategy
Sibling x Sibling
状況
Live Mouse
このマウス系統を論文で使用する場合は、「NKG Mouse(カタログ番号C001316)はサイアジェンから購入しました。」と引用してください。
Immunodeficient Mice
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
お見積もりについてはこちらまでご連絡ください
Immunodeficient Mice

基本情報

検証 Data

関連リソース

基本情報

遺伝子名

Il2rg

遺伝子別名

gc, p64, [g]c, CD132, gamma(c)

NCBI ID

16186

染色体

Chr X

MGI ID

MGI:96551

さらに

希少疾患データセンター >>

データシート

こちらをクリックしてダウンロードしてください >>

系統詳細

NKG mice are a kind of severe immunodeficient mice generated by Cyagen by deleting the Il2rg gene from NOD-Scid genetic background mice. NKG mice exhibit deficiency of mature T cells, B cells, and functional NK cells, reduced complement activity, and weak phagocytosis of human-derived cells by macrophages, which are well suited for transplantation of human hematopoietic stem cells (HSC), peripheral blood mononuclear cells (PBMC), adult stem cells and tissues, and patient-derived xenograft (PDX).
NKG mice are currently recognized as one of the models with the highest degree of immunodeficiency. They are an excellent model that can be widely used for research in the fields of oncology, immunity, autoimmune diseases, immunotherapy, vaccines, graft-versus-host disease (GvHD), and drug safety evaluation.

適用分野

Immune system and tumor immunity research;
Hematopoietic development and blood disorders research;
Infectious disease studies such as HIV and AIDS;
Tumor transplantation and anti-tumor efficacy studies;
CDX, PDX, GvHD, and humanized immune system (HIS) research.
検証 Data

1. Detection of Prkdc gene mutation

MT: TAACGGAAAAGAATTGGTATCCACAACATAAAATACGCTAAGCTAAGAGAAAGTTAGCAGGGGCCAACCCAGCTGTTATA
Figure 1. Mutation type detection of Prkdc gene in NKG mice. The Prkdcsscid mutation was generated by TAT→TAA transition in exon 84 of the Prkdc gene, and gene sequencing results showed that NKG mice carried the Prkdcsscid mutation.

2. Detection of Il2rg knockout

Figure 2. Deletion of Il2rg gene in NKG mice. PCR assay of the Il2rg gene in NKG mice showed successful deletion of the Il2rg gene in NKG mice (Band size of wild-type Il12rg gene: 1430bp; band size of Il12rg gene with partial fragment knocked out: 388bp).

3. Detection of B, T, and NK cells in the Peripheral Blood (PB) of NKG mice

Figure 3. NKG mice showed severe immunodeficiency with severe deficiency of B, T, and NK cells in peripheral blood (PB). The results showed that B cells (CD3-CD19+), T cells (CD3+CD19-), T helper cells (CD3+CD4+CD8-), cytotoxic T cells (CD3+CD4-CD8+), and NK cells (CD335+CD3-) were almost completely absent in the peripheral blood of NKG mice.

4. Detection of B, T, and NK cells in the spleen of NKG mice

Figure 4. NKG mice showed severe immunodeficiency with severe deficiency of B, T, and NK cells in the spleen. The results showed that B cells (CD3-CD19+), T cells (CD3+CD19-), T helper cells (CD3+CD4+CD8-), cytotoxic T cells (CD3+CD4-CD8+), and NK cells (CD335+CD3-) were almost completely absent in the spleen of NKG mice.

5. --

(1)Survival curve
Figure 5. The survival curve of huPBMC-NKG mice. Around 35 days after transplantation, huPBMC-NKG mice gradually began to die as graft-versus-host disease (GvHD) appeared. After 60 days of transplantation, about 20% of the mice were still alive.
(2)Proportion of human leukocytes
Figure 6. The proportion of human CD45+ cells in peripheral blood (PB) of huPBMC-NKG mice. After transplantation of human PBMCs, the content of human leukocytes in the peripheral blood of NKG mice gradually increased. After 3 weeks, the average proportion of human CD45+ cells exceeded 40%, and the reconstruction speed was relatively fast (similar products generally take 4 weeks to reach the same level of humanization ratio). After transplantation, the humanization ratio remained high for 3-6 weeks.
(3)Proportion of T-cell reconstitution
Figure 7. The proportion of human CD3+ T cells in the peripheral blood of huPBMC-NKG mice. About 95%- 100% of hCD45+ cells in NKG mice belong to hCD3+ T cells 3 weeks after human PBMC transplantation, indicating that the reconstruction of the human immune system in huPBMC-NKG mice was dominated by T cells.
(4)The Graft-versus-Host Disease (GvHD)
Figure 8. GvHD scores and body weight changes in NKG mice after PBMC transplantation. GvHD symptoms begin to appear around 28d. Mice lost a significant amount of body weight, and the body weight was reduced by more than 20% after 45d.

6. NKG mice (Adult) for the study in huCD34+ HSC (huHSC) humanized immune system

(1)Survival curve
Figure 9. The survival curve of huHSC-NKG adult mice. The huHSC-NKG adult mice were free of graft-versus-host disease (GvHD) and maintained a high survival rate of over 70% after 150 days post-engraftment.
(2)Growth curve
Figure 10. The growth curve of huHSC-NKG adult mice. The huHSC-NKG adult mice maintained normal weight gain after the transplantation of huHSC.
(3)Proportion of human leukocytes
Figure 11. The proportion of human CD45+ cells in peripheral blood of huHSC-NKG adult mice. The percentage of human leukocytes gradually increased, and the average rate of human CD45+ cells reached more than 60%.
(4)Proportions of human T cells and B cells
Figure 12. Proportions of human T cells and B cells in huHSC-NKG adult mice. The reconstruction of the immune system in this model was dominated by B cells in the early stage. The proportion of B cells gradually decreased and the proportion of T cells gradually increased in the later stage. At 12 weeks post-engraftment, the proportion of T cells began to increase, reaching about 40% at week 16. The proportion of B cells was higher at the early stage, reaching 80%, and decreased to 15% at week 24.
(5)Proportions of human NK cells and monocytes
Figure 13. Proportions of human NK cells and monocytes in huHSC-NKG adult mice. The proportions of NK cells and monocytes during immune system reconstitution were low. The average proportion of NK cells maintained at about 2% overall and the proportion of monocytes at week 16 was about 2%.

7. NKG mice (Newborn) for the study in huHSC humanized immune system

(1)Survival curve
Figure 14. The survival curve of huHSC-NKG newborn mice. The huHSC-NKG newborn mice were free of graft-versus-host disease (GvHD). The survival rate of huHSC-NKG newborn mice maintained more than 90% before 100 days post engraftment and the survival rate still maintained more than 80% nearly 150 days post engraftment, which was higher than that of the adult model.
(2)Growth curve
Figure 15. The growth curve of huHSC-NKG newborn mice. The huHSC-NKG newborn mice maintained normal weight gain after the transplantation of huHSC.
(3)Proportion of human leukocytes
Figure 16. The proportion of human CD45+ cells in peripheral blood of huHSC-NKG newborn mice. The percentage of human leukocytes gradually increased. The average percentage of human CD45+ leukocytes reached more than 40% after 8 weeks post engraftment and subsequently increased and maintained at about 60%.
(4)Proportions of human T cells and B cells
Figure 17. Proportions of human T cells and B cells in huHSC-NKG newborn mice. Similar to the adult model, the reconstruction of the immune system in this model was dominated by B cells in the early stage. The proportion of B cells gradually decreased and the proportion of T cells gradually increased in the later stage. At 12 weeks post-engraftment, the proportion of T cells began to increase, reaching about 40% at week 14. The proportion of B cells was higher than 80% at the early stage and decreased continuously, dropping to 40% at week 20.
(5)Proportions of human NK cells and monocytes
Figure 18. Proportions of human NK cells and monocytes in huHSC-NKG newborn mice. The proportions of NK cells and monocytes were higher in this newborn model than in the adult model. The average percentage of NK cells was more than 10% in the early stage and maintained at about 5% in the later stage. The average percentage of monocytes was higher than 5%. Therefore, the newborn model is more suitable for studies related to myeloid cell targets.

8. NKG mice for the establishment of cell line-derived xenograft (CDX) models

Figure 19. Tumor growth curves after subcutaneous xenografts of various human-derived tumor cells. Tumor cells were inoculated into NKG and NOD-Scid mice by subcutaneous injection at a cell inoculation rate of 5x10^6/each, and tumorigenic volumes were measured at different time points. The results showed that human pancreatic cancer cell line PANC-1, human liver cancer cell line Huh7, human gastric cancer cell line HGC-27, and human colon adenocarcinoma cell line SW620 were effective in establishing tumor models on NKG mice. The rate of tumor growth, as well as size in NKG mice, were better than those in NOD-Scid mice

9. NKG mice for the establishment of a hematological tumor cell transplantation model

Figure 20. Tumor growth in NKG mice after transplantation of human Jurkat cells. Transplant human T-lymphocyte cell line Jurkat with luciferase marker into NKG mice by tail vein injection and subsequently detect tumor growth by fluorescence generation. The results showed that Jurkat lymphocyte cells could grow in NKG mice, indicating the successful establishment of this tumor model.

10. The anti-tumor pharmacodynamics of paclitaxel on the human lymphoma (Raji-Luc) CDX model

Figure 21. The anti-tumor pharmacodynamics of paclitaxel on the human lymphoma (Raji-Luc) CDX model. Transplant human lymphoma (Raji-Luc) cell lines into NKG mice and treat with the anti-cancer drug paclitaxel (PTX) to verify the effect of tumorigenesis in NKG mice and the pharmacodynamic. The results showed that the human lymphoma (Raji-Luc) cell line could grow normally in mice and lead to their death by day 28. In contrast, treatment with paclitaxel (PTX) effectively attenuated tumor development and maintained the survival of mice.

11. Establishment of PANC-1 pancreatic in-situ model using NKG mice

Figure 22. Establishment of a pancreatic in-situ model using NKG mice. After transplanting the human pancreatic cancer cell line PANC-1 into NKG mice, the fluorescent effect, mouse survival, and average total fluorescence value were measured. The results show that the PANC-1 pancreatic in-situ model was successfully established.

12. Establishment of NCI-H441 lung in-situ model using NKG mice

Figure 23. Establishment of a lung in-situ model using NKG mice. After transplanting the human lung cancer cell line NCI-H441 into NKG mice, the fluorescent effect and the average total fluorescence value were measured, and the lung tissue of the mice was observed by dissection. The results show that the NCI-H441 lung in-situ model was successfully established.

13. Establishment of MCF-7-luc breast cancer bone metastasis mouse model using NKG mice

Figure 24. Establishment of a breast cancer bone metastasis mouse model using NKG mice. Human breast cancer MCF-7-luc cells were inoculated into NKG (left) in the form of tibial injection, with a cell inoculation amount of 0.5×106 per mouse. At the same time, MCF-7-luc cells were inoculated into NKG in the form of iliac artery injection, with a cell inoculation amount of 1×106 per mouse (right). The results show that MCF-7-luc can effectively establish a bone metastasis tumor model in NKG mice.

14. H&E Staining

(1)H&E staining of various tissues of NKG mice
Figure 25. Pathological examination of NKG mice. No obvious abnormalities were observed in the lung, liver, heart, kidney, stomach, small intestine, colon, and cervix. However, the spleen lacked white pulp, and lymphocytes were reduced in the spleen and thymus.
(2)H&E staining results of spleen and thymus tissues
Figure 26. Pathological examination of spleen and thymus tissues in wild-type (WT) mice, NOD-Scid mice, and NKG mice. Results show that the spleen structure of wild-type mice is normal, with intact follicles and a normal red-to-white pulp ratio. In contrast, NOD-Scid and NKG mice exhibit a decreased number of lymphocytes and unclear red and white pulp boundaries in the spleen. Additionally, the thymus structure of wild-type mice is normal, whereas the thymuses of NOD-Scid and NKG mice are atrophied, with significantly reduced cortical and medullary lymphocytes.

15. Complete Blood Count (CBC) of 8-week-old NKG mice (n=20, data presented as Mean±SEM)

16. Blood biochemistry (n=8, data presented as Mean±SEM)

17. In vivo tumorigenic validation of human-derived tumor cell lines

*NOD-Scid mice (catalog number: C001070) are immunodeficient mice constructed by introducing the Prkdcscid mutation on a non-obese diabetic mouse (NOD) background strain with innate T and B lymphocyte immunodeficiency. BALB/c Nude mice (catalog number: C001217) are immunodeficient mice lacking mature T lymphocytes. *The specific validation data in this table can be found on the official website.
関連リソース
お問い合わせ
ご不明な点やご質問などございましたら、お気軽にお問い合わせください。担当スタッフがサポートさせていただきます。下記のフォームにご記入いただければ、1〜2営業日以内に折り返しご連絡いたします。
お名前
メール
電話番号
ご所属機関
職務
主な研究分野
関心のあるサービス
メッセージ
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。

Related Product

All Related Products
--
--
もっと見る
--
--
もっと見る
--
--
もっと見る

Resources

詳細を見る

Publications

Nature
2026-03-17
Proteasome-guided haem signalling axis contributes to T cell exhaustion
続きを読む
Nature
2026-03-18
Proteasome-guided haem signalling axis contributes to T cell exhaustion
続きを読む
Signal Transduction and Targeted Therapy
2024-06-23
Engineered extracellular vesicles for targeted reprogramming of cancer-associated fibroblasts to potentiate therapy of pancreatic cancer
続きを読む
Nature Cancer
2025-03-17
A Gremlin 1-expressing splenic niche cell population restrains chronic myeloid leukemia by antagonizing the BMP pathway
続きを読む
Nature Communications
2026-04-24
RPSA-OLFM4 axis governs neutrophil migration against bacterial infection and sepsis
続きを読む
Nature Communications
2024-12-29
An antibody cocktail targeting two different CD73 epitopes enhances enzyme inhibition and tumor control
続きを読む
Nature Communications
2024-10-19
Iron-loaded cancer-associated fibroblasts induce immunosuppression in prostate cancer
続きを読む
Advanced Science
2024-02-21
RECQL4 Inhibits Radiation‐Induced Tumor Immune Awakening via Suppressing the cGAS‐STING Pathway in Hepatocellular Carcinoma
続きを読む
Advanced Science
2025-01-21
A Novel 167‐Amino Acid Protein Encoded by CircPCSK6 Inhibits Intrahepatic Cholangiocarcinoma Progression via IKBα Ubiquitination
続きを読む
Autophagy
2025-04-10
Inhibition of PINK1 senses ROS signaling to facilitate neuroblastoma cell pyroptosis
続きを読む
Advanced Science
2025-01-20
A Novel 167-Amino Acid Protein Encoded by CircPCSK6 Inhibits Intrahepatic Cholangiocarcinoma Progression via IKBα Ubiquitination
続きを読む
Science Advances
2025-12-31
Multidimensional mapping of stimulation-responsive regulatory elements and candidate causal variants in T cell activation
続きを読む
Theranostics
2025-03-21
FOS-driven inflammatory CAFs promote colorectal cancer liver metastasis via the SFRP1-FGFR2-HIF1 axis
続きを読む
MedComm
2024-10-21
Feedback loop LINC00511–YTHDF2–SOX2 regulatory network drives cholangiocarcinoma progression and stemness
続きを読む
Cancer Immunology Research
2023-01-02
Enhancing the Antitumor Immunity of T Cells by Engineering the Lipid-Regulatory Site of the TCR/CD3 Complex
続きを読む
ACS Materials Letters
2024-08-17
Bacterial Programmed Cell Death Induced by Nanotherapeutic Strategies
続きを読む
Acta Biomaterialia
2023-08-31
PTT/ PDT-induced microbial apoptosis and wound healing depend on immune activation and macrophage phenotype transformation
続きを読む
Pharmacological Research
2024-09
Developing patient-derived organoids to demonstrate JX24120 inhibits SAMe synthesis in endometrial cancer by targeting MAT2B
続きを読む
Molecular Therapy
2025-02-04
Single-cell data-driven design of armed oncolytic virus to boost cooperative innate-adaptive immunity against cancer
続きを読む
Materials Today Bio
2024-06
Enhancing glioma-specific drug delivery through self-assembly of macrophage membrane and targeted polymer assisted by low-frequency ultrasound irradiation
続きを読む
Cell Death & Disease
2025-04-11
Interleukin-33 (IL-33) promotes DNA damage-resistance in lung cancer
続きを読む
International Journal of Nanomedicine
2023-10-04
The Therapeutic Effects of MUC1-C shRNA@Fe3O4 Magnetic Nanoparticles in Alternating Magnetic Fields on Triple-Negative Breast Cancer
続きを読む
International Journal of Biological Sciences
2025-01-19
SERINC2-mediated serine metabolism promotes cervical cancer progression and drives T cell exhaustion
続きを読む
Neoplasia
2025-06-29
DHX34 deficiency triggers tumor-intrinsic immunity via a dsRNA-mediated type I interferon pathway activation in HCC
続きを読む
Cell Reports
2025-05
Tumor microenvironment-associated oxidative stress impairs SIRT1 secretion to suppress anti-tumor immune response
続きを読む
Journal of Translational Medicine
2026-05-13
KLRG1 silencing increases the efficacy of CAR NK cell therapy against colon cancer via SHP-2/ZAP-70/NF-κB signal pathway
続きを読む
Journal of Translational Medicine
2024-02-17
Combined therapy of CAR-IL-15/IL-15Rα-T cells and GLIPR1 knockdown in cancer cells enhanced anti-tumor effect against gastric cancer
続きを読む
Microbial Cell Factories
2023-05-16
Manufacture and evaluation of a HER2-positive breast cancer immunotoxin 4D5Fv-PE25
続きを読む
Frontiers in Immunology
2025-01-16
A self-activated and protective module enhances the preclinical performance of allogeneic anti-CD70 CAR-T cells
続きを読む
Cancers
2022-12-06
Role of Epidermal Growth Factor Receptor-Specific CAR-T Cells in the Suppression of Esophageal Squamous Cell Carcinoma
続きを読む
Cancer Immunology, Immunotherapy
2025-12-18
Preclinical evaluation of CAR-T cell immunotherapy with a fully human EpCAM-specific scFv against pancreatic cancer
続きを読む
ACS Pharmacology & Translational Science
2024-11-25
Gallium-68 Labeled Positron Emission Computed Tomography Tracer Targeting Glypican-3 with High Contrast for Hepatocellular Carcinoma Imaging
続きを読む
British Journal of Haematology
2024-07-02
Development of novel humanized CD19/BAFFR bicistronic chimeric antigen receptor T cells with potent antitumor activity against B-cell lineage neoplasms
続きを読む
Life
2025-07-18
Human Immune System Reconstitution in NOD/Shi-Prkdcscid Il2rgem1/Cyagen Mice to Study HIV Infection: Challenges and Pitfalls
続きを読む
BMC Cancer
2022-09-08
MYBL2 regulates de novo purine synthesis by transcriptionally activating IMPDH1 in hepatocellular carcinoma cells
続きを読む
Scientific Reports
2025-03-14
YTHDC1 negatively regulates UBE3A to influence RAD51 ubiquitination and inhibit apoptosis in colorectal cancer cells
続きを読む
Regenerative Therapy
2024-03-25
Denosumab ameliorates osteoarthritis by protecting cartilage against degradation and modulating subchondral bone remodeling
続きを読む
Heliyon
2024-01-29
The construction, validation and promotion of the nomogram prognosis prediction model of UCEC, and the experimental verification of the expression and knockdown of the key gene GPX4
続きを読む
PLOS ONE
2024-09-24
TFAB002s, novel CD20-targeting T cell-dependent bispecific Fab-FabCH3 antibodies, exhibit potent antitumor efficacy against malignant B-cell lymphoma
続きを読む
Discover Oncology
2024-04-01
Cyclovirobuxine D inhibits hepatocellular carcinoma growth by inducing ferroptosis of hepatocellular carcinoma cells
続きを読む
Stem Cell Research
2024-12
Human induced pluripotent stem cell line (FDHSi005-A) derived from a patient with a deep intronic variant in the GNE gene
続きを読む
Molecular Therapy
2025-02-05
Single-cell data-driven design of armed oncolytic virus to boost cooperative innate-adaptive immunity against cancer
続きを読む
International Journal of Biological Sciences
2025-01-20
SERINC2-mediated serine metabolism promotes cervical cancer progression and drives T cell exhaustion
続きを読む
Signal Transduction and Targeted Therapy
2024-06-24
Engineered extracellular vesicles for targeted reprogramming of cancer-associated fibroblasts to potentiate therapy of pancreatic cancer
続きを読む
Discover Oncology
2024-04-02
Cyclovirobuxine D inhibits hepatocellular carcinoma growth by inducing ferroptosis of hepatocellular carcinoma cells
続きを読む
BMC Cancer
2022-09-09
MYBL2 regulates de novo purine synthesis by transcriptionally activating IMPDH1 in hepatocellular carcinoma cells
続きを読む
ACS Materials Letters
2024-08-18
Bacterial Programmed Cell Death Induced by Nanotherapeutic Strategies
続きを読む
Heliyon
2024-01-30
The construction, validation and promotion of the nomogram prognosis prediction model of UCEC, and the experimental verification of the expression and knockdown of the key gene GPX4
続きを読む
International Journal of Nanomedicine
2023-10-05
The Therapeutic Effects of MUC1-C shRNA@Fe3O4 Magnetic Nanoparticles in Alternating Magnetic Fields on Triple-Negative Breast Cancer
続きを読む
预印本
2023-03-29
Extensive Dysregulation of SLK Splicing in Cancers Impacts Metastasis
続きを読む
Cancer Immunology Research
2023-01-03
Enhancing the Antitumor Immunity of T Cells by Engineering the Lipid-Regulatory Site of the TCR/CD3 Complex
続きを読む
Frontiers in Immunology
2025-01-17
A self-activated and protective module enhances the preclinical performance of allogeneic anti-CD70 CAR-T cells
続きを読む
Stem Cell Research
2024-12-01
Human induced pluripotent stem cell line (FDHSi005-A) derived from a patient with a deep intronic variant in the GNE gene
続きを読む
Nature Communications
2024-12-30
An antibody cocktail targeting two different CD73 epitopes enhances enzyme inhibition and tumor control
続きを読む
The EMBO Journal
2025-01-28
Micropeptide hSPAR regulates glutamine levels and suppresses mammary tumor growth via a TRIM21-P27KIP1-mTOR axis
続きを読む
Preprint
2023-03-28
Extensive Dysregulation of SLK Splicing in Cancers Impacts Metastasis
続きを読む
Advanced Science
2025-01-21
A Novel 167-Amino Acid Protein Encoded by CircPCSK6 Inhibits Intrahepatic Cholangiocarcinoma Progression via IKBα Ubiquitination
続きを読む
PLoS ONE
2024-09-25
TFAB002s, novel CD20-targeting T cell-dependent bispecific Fab-FabCH3 antibodies, exhibit potent antitumor efficacy against malignant B-cell lymphoma
続きを読む
British Journal of Haematology
2024-07-03
Development of novel humanized CD19/BAFFR bicistronic chimeric antigen receptor T cells with potent antitumor activity against B-cell lineage neoplasms
続きを読む
Acta Biomaterialia
2023-09-01
PTT/ PDT-induced microbial apoptosis and wound healing depend on immune activation and macrophage phenotype transformation
続きを読む
Nature Communications
2024-10-20
Iron-loaded cancer-associated fibroblasts induce immunosuppression in prostate cancer
続きを読む
Materials Today Bio
2024-06-01
Enhancing glioma-specific drug delivery through self-assembly of macrophage membrane and targeted polymer assisted by low-frequency ultrasound irradiation
続きを読む
ACS Pharmacology & Translational Science
2024-11-26
Gallium-68 Labeled Positron Emission Computed Tomography Tracer Targeting Glypican-3 with High Contrast for Hepatocellular Carcinoma Imaging
続きを読む
Cancers
2022-12-07
Role of Epidermal Growth Factor Receptor-Specific CAR-T Cells in the Suppression of Esophageal Squamous Cell Carcinoma
続きを読む
Pharmacological Research
2024-09-01
Developing patient-derived organoids to demonstrate JX24120 inhibits SAMe synthesis in endometrial cancer by targeting MAT2B
続きを読む
Microbial Cell Factories
2023-05-17
Manufacture and evaluation of a HER2-positive breast cancer immunotoxin 4D5Fv-PE25
続きを読む
Taylor & Francis
2024-09-30
Anti-HER2 biparatopic antibody KJ015 has near-native structure, functional balanced high affinity, and synergistic efficacy with anti-PD-1 treatment in vivo
続きを読む
MedComm
2024-10-22
Feedback loop LINC00511–YTHDF2–SOX2 regulatory network drives cholangiocarcinoma progression and stemness
続きを読む
Taylor & Francis
2024-10-01
Anti-HER2 biparatopic antibody KJ015 has near-native structure, functional balanced high affinity, and synergistic efficacy with anti-PD-1 treatment in vivo
続きを読む
Journal of Translational Medicine
2024-02-18
Combined therapy of CAR-IL-15/IL-15Rα-T cells and GLIPR1 knockdown in cancer cells enhanced anti-tumor effect against gastric cancer
続きを読む
The EMBO Journal
2025-01-27
Micropeptide hSPAR regulates glutamine levels and suppresses mammary tumor growth via a TRIM21-P27KIP1-mTOR axis
続きを読む
Items: 1 to 5 of 71
1
2
3
4
5
6
...
14
15
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
お問い合わせ内容
主な研究分野
関心のあるサービス
ターゲット遺伝子
プロジェクト詳細
当社を知りなったきっかけ?
連絡先情報
お名前
メール
電話番号
ご所属機関
職務
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
モデルライブラリ
モデルライブラリ
リソース
リソース
動物の品質
動物の品質
サポートを受ける
サポートを受ける
住所:
〒543-0071 大阪府大阪市天王寺区生玉町2-3 小出ビル410室
電話 :
06-7652-3321
メール:
[email protected]
モデル製品
HUGO-Ab™(抗体開発)HUGO-GT™(ヒト化ゲノムオルソログ)MouseAtlas モデルライブラリ研究用動物モデル
サービス
神経科学眼科分野がん研究代謝・循環器系疾患自己免疫・炎症疾患
会社案内
企業概要施設概要動物の健康・福祉健康報告書協力企業・代理店採用情報お問い合わせ
SNS
免責事項:当社の製品およびサービスの価格や入手可能性は地域によって異なります。記載されている価格は特定の国々に適用されます。詳細についてはご連絡ください。
Copyright © 2025 Cyagen. All rights reserved.
プライバシーポリシー
サイトマップ
Cyagenの最新情報をお届けします
研究モデル、CROサービス、科学リソース、特別オファーに関する最新情報を、研究ニーズに合わせてメールでお届けします。
お名前
メール
ご所属機関
関心分野
主な研究分野